NEET-PG 2013 - Biochemistry Practice Questions

Q: Which enzyme catalyzes oxidative deamination?

Glutamate dehydrogenase. ***Glutamate dehydrogenase*** - This enzyme catalyzes the conversion of **glutamate** to **α-ketoglutarate** and ammonia (NH₃), which is an oxidative deamination reaction. - It utilizes **NAD⁺ or NADP⁺** as a coenzyme to remove hydrogen atoms during the oxidation process. - Plays a crucial role in both **amino acid catabolism** and anabolism. *Glutaminase* - This enzyme hydrolyzes **glutamine** to glutamate and ammonia, which is a **hydrolytic deamidation** reaction, not an oxidative deamination. - It does not involve the oxidation of the substrate or require NAD⁺/NADP⁺ as cofactors. *Glutamine synthase* - This enzyme synthesizes **glutamine** from glutamate and ammonia, using ATP, which is a **biosynthetic** reaction, not a catabolic deamination. - It is involved in **ammonia detoxification** and amino acid synthesis, functioning in the opposite direction of deamination. *None of the options* - This option is incorrect because **glutamate dehydrogenase** is a valid correct answer. - Glutamate dehydrogenase is the primary enzyme responsible for oxidative deamination in human metabolism.

Q: Transamination of Aspartate forms which compound?

Oxaloacetate. ***Oxaloacetate*** - **Aspartate** is transaminated by **aspartate aminotransferase (AST)**, transferring its alpha-amino group to **alpha-ketoglutarate**. - This reaction converts aspartate into its corresponding alpha-keto acid, which is **oxaloacetate**. *Pyruvate* - **Pyruvate** is the alpha-keto acid corresponding to the amino acid **alanine**. - Transamination of **alanine** yields **pyruvate**, not aspartate. *Acetyl-CoA* - **Acetyl-CoA** is not a direct product of amino acid transamination; it is formed from **pyruvate** or fatty acid oxidation. - It functions as a key metabolic intermediate in energy production and biosynthesis. *Alanine* - **Alanine** is an amino acid, and therefore a reactant in transamination reactions to form pyruvate, rather than a product of aspartate transamination. - While it can be formed from pyruvate via transamination, it is not formed from aspartate.

Q: Which defect in the urea cycle is an X-linked disease?

Ornithine transcarbamylase. ***Ornithine transcarbamylase*** - **Ornithine transcarbamylase (OTC) deficiency** is the only **X-linked recessive** disorder among the urea cycle defects. - Males are usually more severely affected, while females can be symptomatic carriers. *Carbamoyl phosphate synthetase I* - **Carbamoyl phosphate synthetase I (CPS1) deficiency** is an **autosomal recessive** disorder. - It is one of the more severe urea cycle defects, leading to profound hyperammonemia. *Arginase* - **Arginase deficiency** (hyperargininemia) is an **autosomal recessive** disorder. - It typically presents with a distinct neurological phenotype, including spasticity and developmental delay. *Argininosuccinate synthase* - **Argininosuccinate synthase deficiency**, also known as **Citrullinemia type I**, is an **autosomal recessive** disorder. - It leads to the accumulation of **citrulline** and **ammonia** in the blood.

Q: What is the primary enzymatic source of ammonia production in urine?

Glutaminase. ***Glutaminase*** - This enzyme catalyzes the **hydrolysis of glutamine** located predominantly in the cells of the **renal tubules**, producing **ammonia** (NH3) and glutamate. - This process is crucial for **acid-base balance**, as the ammonia can bind with excess hydrogen ions to form ammonium (NH4+), which is then excreted in the urine. *Urease* - This enzyme breaks down **urea into ammonia and carbon dioxide**, primarily produced by **bacteria**, not human renal cells, and contributes to ammonia in urine in cases of **urinary tract infections**. - While it produces ammonia, it is not the primary enzymatic source within the healthy human kidney for **acid-base regulation**. *Glutamate dehydrogenase* - This enzyme converts **glutamate into alpha-ketoglutarate and ammonia**, but its contribution to urinary ammonia production is secondary to glutaminase in the kidney. - Its primary role is in **oxidative deamination** and the interconversion of glutamate and alpha-ketoglutarate, acting in both mitochondrial and cytosolic compartments. *Arginase* - This enzyme is involved in the **urea cycle**, converting **arginine into urea and ornithine** in the liver. - While it is important for the detoxification of ammonia by converting it into urea for excretion, it **does not produce ammonia** in the kidney for urinary excretion.

Q: Which amino acids accumulate in maple syrup urine disease?

All branched-chain amino acids. ***All branched-chain amino acids*** - Maple syrup urine disease (MSUD) is characterized by a deficiency in the **branched-chain alpha-keto acid dehydrogenase complex**, which is responsible for the breakdown of branched-chain amino acids (BCAAs). - This deficiency leads to the accumulation of **leucine, isoleucine, and valine**, along with their corresponding alpha-keto acids, in the blood and urine. - The distinctive **maple syrup odor** in the urine is caused by the accumulation of branched-chain keto acids derived from all three BCAAs. *Leucine* - While leucine is one of the BCAAs that accumulates in MSUD, it is not the *only* amino acid involved. - The accumulation of **leucine** is particularly associated with the severe neurological symptoms seen in MSUD, as it is the most neurotoxic of the three BCAAs. *Valine* - Valine is another BCAA that accumulates due to the metabolic block in MSUD. - However, the disease involves the accumulation of all three BCAAs, not just valine in isolation. *Isoleucine* - Isoleucine is the third BCAA that accumulates in MSUD due to the defective enzyme. - Like leucine and valine, isoleucine and its corresponding keto acid accumulate in blood and urine when the branched-chain alpha-keto acid dehydrogenase complex is deficient.

Q: What is the primary effect of moderate alcohol consumption on cholesterol levels?

High-Density Lipoprotein (HDL). ***High-Density Lipoprotein (HDL)*** - Moderate alcohol consumption is known to **increase HDL cholesterol** levels. - HDL cholesterol helps in the **reverse cholesterol transport**, removing excess cholesterol from tissues and transporting it back to the liver for excretion. *Total cholesterol* - The effect of moderate alcohol on **total cholesterol** is less consistent and may vary, as it is a sum of HDL, LDL, and 20% of VLDL. - While HDL increases, other components might remain unchanged or show minimal variation, thus not making it the primary and direct effect. *Low-Density Lipoprotein (LDL)* - Moderate alcohol consumption generally has **little to no significant effect** on **LDL cholesterol** levels. - Some studies suggest a slight decrease or no change, but it is not the primary lipid affected. *Very Low-Density Lipoprotein (VLDL)* - There is generally **no significant direct effect** of moderate alcohol consumption on **VLDL cholesterol** levels. - Excessive alcohol intake, however, can elevate triglycerides, which are the main component of VLDL particles.

Q: What is the number of variable regions present on each light and heavy chain of an antibody?

1. ***1*** - Each **light chain** and **heavy chain** within an antibody molecule contains **one variable region (V domain)**. - These variable regions are crucial for **antigen binding specificity**, as they combine to form the antigen-binding site. - The variable domain is located at the **N-terminal end** of each chain. *2* - While a complete antibody molecule has **two antigen-binding sites** (bivalent), each formed by pairing of VH and VL domains, individual chains possess only **one variable region each**. - The number '2' refers to the total number of identical binding sites on the intact antibody, not the number of variable regions per chain. *3* - The number **3** does not correspond to the number of variable regions on individual chains. - This might be confused with the **three complementarity-determining regions (CDRs)** present within each variable domain (CDR1, CDR2, CDR3), which are hypervariable loops that directly contact the antigen. *4* - The number **4** is incorrect for variable regions. - This number corresponds to the total number of **polypeptide chains** in a complete IgG antibody (2 heavy + 2 light chains), or the number of **constant domains** in some heavy chain isotypes (IgM, IgE have 4 CH domains).

Q: Clinical effect of vitamin D is reduced by ?

Simultaneous ingestion of phytates. ***Simultaneous ingestion of phytates*** - **Phytates (phytic acid)** found in whole grains, nuts, seeds, and legumes can **reduce the clinical effect of vitamin D** through multiple mechanisms - Phytates **chelate calcium** and form insoluble calcium-phytate complexes, reducing calcium absorption - Since **vitamin D and calcium metabolism are closely linked**, impaired calcium absorption indirectly reduces vitamin D efficacy - Phytates can also **directly bind to vitamin D** in the gastrointestinal tract, reducing its bioavailability - Studies show that **high phytate intake increases vitamin D requirements** and can impair vitamin D status *Simultaneous ingestion of lactose* - Lactose does **not reduce** vitamin D absorption or efficacy - In fact, **dairy products are commonly fortified** with vitamin D, and the presence of lactose does not interfere with its beneficial effects - Lactose may actually **enhance calcium absorption**, which works synergistically with vitamin D *Acidic environment* - Vitamin D is a **fat-soluble vitamin** absorbed primarily in the small intestine - An acidic environment (stomach acid) is **not known to inhibit** vitamin D absorption - The absorption process occurs in the **alkaline environment of the small intestine** where fat-soluble vitamins are absorbed with dietary fats *None of the options* - This is **incorrect** as phytates do reduce the clinical effect of vitamin D through calcium chelation and direct binding mechanisms

Q: In which condition is the Albumin to Globulin (A:G) ratio maintained?

Nephritic syndrome. ***Nephritic syndrome*** - In nephritic syndrome, the **glomerular filtration is often preserved**, allowing for the maintenance of A:G ratio despite the presence of hematuria and proteinuria [1]. - The condition typically leads to a **moderate degree of proteinuria**, retaining a relatively normal serum albumin level [1]. *Multiple myeloma* - In multiple myeloma, there is often a **high level of paraproteins** leading to a significant drop in albumin, affecting the A:G ratio. - Patients frequently exhibit **renal impairment**, resulting in a disrupted A:G ratio due to increased urinary protein loss. *Protein losing enteropathy* - This condition causes **loss of proteins** like albumin through the gastrointestinal tract, leading to **hypoalbuminemia** and altered A:G ratio. - It is characterized by **diarrhea** and fluid accumulation, further impacting the protein status in circulation. *Cirrhosis* - Cirrhosis leads to **decreased albumin synthesis**, resulting in a low serum albumin and an altered A:G ratio. - The condition is associated with **portal hypertension** and ascites, complicating the biochemical status.

Q: Which of the following conditions is primarily treated with Vitamin B6?

Homocystinuria. ***Homocystinuria*** - The most common form of **homocystinuria** is caused by **cystathionine β-synthase (CBS) deficiency**, which requires **pyridoxal phosphate (Vitamin B6)** as a cofactor. - Approximately **50% of patients** with CBS deficiency are **B6-responsive**, making **high-dose Vitamin B6 (100-500 mg/day)** a **first-line primary treatment** for these cases. - This is a **clinically significant condition** that requires treatment, manifesting with features like **ectopia lentis, marfanoid habitus, intellectual disability, and thromboembolism**. - B6 supplementation enhances residual CBS enzyme activity and reduces plasma homocysteine levels. *Cystathionuria* - Caused by **cystathionine γ-lyase deficiency**, which also uses **Vitamin B6** as a cofactor. - This is generally a **benign, asymptomatic condition** that does **NOT require treatment**. - While B6 can reduce cystathionine accumulation, it is **not a primary treatment indication** because the condition is clinically insignificant. *Xanthurenic aciduria* - Caused by **kynureninase deficiency** in the **tryptophan metabolism pathway**, which requires **pyridoxal phosphate**. - This is a **rare and usually benign condition** that does not typically require treatment. - Not a primary indication for B6 therapy. *None of the options* - Incorrect, as **Homocystinuria** (CBS deficiency) is a **primary indication** for high-dose Vitamin B6 therapy in B6-responsive patients.

Question 1

Which enzyme catalyzes oxidative deamination?

Accepted Answer

Glutamate dehydrogenase

Answer

Glutaminase

Answer

Glutamine synthase

Answer

None of the options

Question 2

Transamination of Aspartate forms which compound?

Accepted Answer

Oxaloacetate

Answer

Pyruvate

Answer

Acetyl-CoA

Answer

Alanine

Question 3

Which defect in the urea cycle is an X-linked disease?

Accepted Answer

Ornithine transcarbamylase

Answer

Arginase

Answer

Argininosuccinate synthase

Answer

Carbamoyl phosphate synthetase I

Question 4

What is the primary enzymatic source of ammonia production in urine?

Accepted Answer

Glutaminase

Answer

Urease

Answer

Glutamate dehydrogenase

Answer

Arginase

Question 5

Which amino acids accumulate in maple syrup urine disease?

Accepted Answer

All branched-chain amino acids

Answer

Valine

Answer

Leucine

Answer

Isoleucine

Question 6

What is the primary effect of moderate alcohol consumption on cholesterol levels?

Accepted Answer

High-Density Lipoprotein (HDL)

Answer

Total cholesterol

Answer

Low-Density Lipoprotein (LDL)

Answer

Very Low-Density Lipoprotein (VLDL)

Question 7

What is the number of variable regions present on each light and heavy chain of an antibody?

Accepted Answer

1

Answer

2

Answer

3

Answer

4

Question 8

Clinical effect of vitamin D is reduced by ?

Accepted Answer

Simultaneous ingestion of phytates

Answer

Simultaneous ingestion of lactose

Answer

None of the options

Answer

Acidic environment

Question 9

In which condition is the Albumin to Globulin (A:G) ratio maintained?

Accepted Answer

Nephritic syndrome

Answer

Cirrhosis

Answer

Protein losing enteropathy

Answer

Multiple myeloma

Question 10

Which of the following conditions is primarily treated with Vitamin B6?

Accepted Answer

Homocystinuria

Answer

Cystathionuria

Answer

None of the options

Answer

Xanthourenic aciduria

NEET-PG 2013 — Biochemistry